期刊文献+

ADAM9特异性siRNA对肾透明细胞癌786-0细胞ADAM9基因表达及体外侵袭能力的影响 被引量:1

Effect of ADAM9 targeted siRNA on ADAM9 gene expression and invasion capacity of renal clear cell carcinoma 786-0 cells in vitro
下载PDF
导出
摘要 目的:探讨去整合素金属蛋白酶9(ADAM9)特异性siRNA对人肾透明细胞癌(RCCC)786-0细胞中ADAM9基因表达及体外侵袭能力的影响。方法:设计合成ADAM9特异性siRNA。将786-0细胞分4组处理,分别为正常对照组(正常培养786-0细胞)、空脂质体转染组、阴性转染组(转染无义siRNA)和ADAM9 siRNA转染组。转染24、48、72 h后,采用RT-PCR法检测细胞ADAM9 mRNA的表达;转染48 h后,采用Western blot法检测细胞ADAM9蛋白的表达,并用Transwell法检测细胞侵袭能力。结果:转染24、48、72 h后,ADAM9 siRNA转染组786-0细胞ADAM9 mRNA的表达显著低于其他3组(F=47.945、180.456、60.978,P均<0.001);转染48 h后,ADAM9 siRNA转染组786-0细胞ADAM9蛋白表达显著降低(F=142.816,P<0.001),穿膜细胞数显著减少(F=45.389,P<0.001)。结论:ADAM9特异性siRNA能够有效沉默786-0细胞中ADAM9的表达并降低其体外侵袭能力。 Aim:To explore the effect of a disintegrin and metalloprotease 9 ( ADAM9 ) targeted siRNA on ADAM9 gene expression and invasion capacity of renal clear cell carcinoma 786-0 cells.Methods:ADAM9 specific siRNA was de-signed and synthesized .786-0 cells were divided into 4 group:normal cultured group , Lipofectamine TM 2000 transfection group, unrelated sequence siRNA (NC siRNA)transfection group and ADAM9 specific siRNA transfection group.RT-PCR was applied to detect ADAM9 mRNA in 786-0 cells after transfection for 24,48,and 72 h.ADAM9 protein was detected by Western blot after transfection for 48 h, and cell invasion was detected with Transwell .Results:The expression of ADAM9 mRNA in ADAM9 specific siRNA transfection group after transfection for 24,48, and 72 h were lower ( F =47.945,&amp;nbsp;180.456,60.978,P&lt;0.001),and ADAM9 protein expression and invasion capacity were significantly lower after transfec-tion for 48 h(F=142.816,45.389,P&lt;0.001).Conclusion:ADAM9 specific siRNA can silence ADAM9 gene in 786-0 cells and inhibit its invasion .
出处 《郑州大学学报(医学版)》 CAS 北大核心 2014年第1期59-62,共4页 Journal of Zhengzhou University(Medical Sciences)
  • 相关文献

参考文献6

二级参考文献49

  • 1杜贤进,张杰.分子靶向药物舒尼替尼治疗肾细胞癌[J].世界临床药物,2009,30(11):657-661. 被引量:3
  • 2侯桂琴,范天黎,鲁照明,刘兰琦,许培荣,薛乐勋,王建人.EC9706和Eca109细胞中雷帕霉素靶蛋白信号通路激活状态观察[J].郑州大学学报(医学版),2007,42(2):223-225. 被引量:11
  • 3Ryan CW,Goldman BH,Lara PJ,et al.Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma:a phase Ⅱ study of the Southwest Oncology Group[J].J Clin Oncol,2007,25:3296-3301.
  • 4Tannir NM,Zurita AI,Heymach JV.A randomized phase ii trial of sorafenib versus sorafenib plus low -dose interferon-alfa:clinical results and biomarker analysis[abstract 5093] [J].Proc Am Soc Clin Oncol,2008,26:S272.
  • 5Tomasello L,Sertoli M,Rubagotti A,et al.Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC):A phase Ⅱ study,preliminary results[J].J Clin Oncol,2008,26:16011.
  • 6Sosman KT,Flaherty MB,Atkins,et al.Updated results of phase Ⅰ trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)[J].J Clin Oncol,26,2008:5011.
  • 7Rosenberg J,Weinberg V,Claros C,et al.Phase Ⅰ study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma[J].J Clin Oncol,2008,26:5109.
  • 8Motzer RJ,Hutson TE,Tomczak P,et al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.[J].J Clin Oncol,2009,27:3584-3590.
  • 9Hariharan S,Szczylik C,Ports C,et al.Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets):data from an expanded access trial[J].J Clin Oncol,2008,26:5094.
  • 10Gore ME,Szczylik C,Porta C,et al.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma:an expanded-access trial[J].Lancet Oncol,2009,10:757-763.

共引文献57

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部